Femoral neck bone mineral density (BMD), age plus femoral neck BMD T score, and three externally generated fracture risk tools had similar accuracy to identify older men who developed osteoporotic fractures. Risk tools with femoral neck BMD performed better than those without BMD. The externally developed risk tools were poorly calibrated.
Introduction
We compared the performance of fracture risk assessment tools in older men, accounting for competing risks including mortality.
Methods
A comparative ROC curve analysis assessed the ability of the QFracture, FRAX® and Garvan fracture risk tools, and fem-
Introduction
In the setting of a US Preventive Services Task Force Grade I (insufficient) evidence grade for male osteoporosis screening [1] , optimal preventive bone health care is undefined for older men. Fewer good-quality trials of osteoporosis treatment have been conducted in men compared with women, and trials focused on male participants are less likely to have a preventive purpose [2, 3] . Male patients and primary care physicians appear to have low awareness of male osteoporosis [4] , with typically low rates of bone mineral density (BMD) testing [5] . In the USA, Medicare insurance only covers BMD testing in men for a limited number of disease conditions, not including routine screening [6] . While fracture risk assessment tools have been developed for use in osteoporosis screening in primary care settings, uptake in clinical practice is low for male patients, even in high-risk men with secondary causes of BMD loss [7] .
While the benefits and risks of routine BMD screening and osteoporosis treatment in men remain uncertain, risk assessment tools available since 2007 may offer a feasible and lowcost way to assess fracture risk and potential need for antifracture treatment. Of these, the FRAX® [8] , Garvan algorithm [9] , and QFracture [10] are the best studied that can be applied to older men [11] , and the reported accuracy of these tools is similar in both sexes [12] . FRAX® was constructed based on primary data from nine population-based cohorts internationally and includes treatment thresholds individualized for 57 countries including the USA [13, 14] . FRAX® incorporates 11 clinical risk factors for a designated country and ethnic group and can be calculated with or without BMD. The Garvan algorithm [15] was developed from 15 years of follow-up data from 858 men and 1358 women aged 60+ years at baseline from the Dubbo Osteoporosis Epidemiology Study in Australia. The Garvan tool incorporates five clinical risk factors and can be calculated with or without BMD. The QFracture tool [16] was developed and internally validated in a UK database comprising 3.7 million patients, contributing 50,755 osteoporotic fractures, 19,531 hip fractures, and 25 million person years. QFracture incorporates 25 clinical risk factors and is calculated without BMD. The tools generate risks of osteoporotic fracture or hip fracture over 10 years (FRAX), 5 or 10 years (Garvan), or 1 to 10 years (QFracture). The FRAX® and Garvan tools have been validated, and all three tools have been independently studied more than once in a population-based setting [12] . A 2017 retrospective cohort study using data from external electronic health records from patients aged 50 and older compared all three tools and concluded that QFracture and FRAX had high discriminatory power for hip fracture prediction [17] .
Previous diagnostic accuracy analyses of hip fracture prediction have rarely considered the competing risks of clinical vertebral fracture, osteoporosis by BMD criteria, antifracture treatment, or death. If individuals develop any of these conditions, risk factor assessment is no longer needed for a treatment decision because treatment is already indicated, in progress, or no longer possible. Methods to account for competing risks avoid inaccurate estimation of the number of fracture events that might be prevented by risk assessment.
We conducted a comparative diagnostic accuracy analysis of the FRAX®, Garvan algorithm, and QFracture in a cohort of community-dwelling men aged 65 years and older without hip or clinical vertebral fracture, antifracture treatment, or osteoporosis (if BMD was included in the risk score) at baseline, accounting for competing risks that occurred at baseline or during follow-up. We hypothesized that risk scores calculated with BMD would have better discriminatory ability than BMD alone or risk scores calculated without BMD. Based on a 2009 comparison of the FRAX tool to age plus BMD or age plus previous fracture in older women [18] , we also hypothesized that simple tools (e.g., BMD T score with or without age) would perform as accurately as more complicated fracture risk tools in older men.
Methods

Setting and participants
The Osteoporotic Fractures in Men (MrOS) study cohort comprised 5994 community-dwelling, ambulatory men aged 65 years and older recruited beginning in March 2000 who received serial dual-energy X-ray absorptiometry (DXA) measurements, lateral thoracic and lumbar spine X-rays, and fracture follow-up over an average of 15.8 years [19, 20] . Participants were also followed every 4 months by postcard or telephone to ascertain fractures that were adjudicated by central review of radiology reports [19] . The study protocol and consent documents were approved by Institutional Review Board review committees at six clinical sites in the USA (Birmingham, AL; Minneapolis, MN; Palo Alto, CA; Pittsburgh, PA; Portland, OR; San Diego, CA). The plan for the current analysis was approved by the Institutional Review Board at the University of North Carolina.
Men were eligible for the analysis of fracture risk scores calculated with BMD if they did not have a history of hip or clinical vertebral fracture, past or current US Food and Drug Administration-approved antifracture treatment (bisphosphonate, calcitonin, or teriparatide), or osteoporosis by BMD criteria at baseline (Online supplement eFigs. 1 and 2). Men were eligible for the analysis of fracture risk scores calculated without BMD if they did not report a previous hip or clinical vertebral fracture or past or current treatment at baseline.
Definition of osteoporosis
Osteoporosis was defined according to the 1994 WHO Technical Report [21] as BMD T score ((BMD of participant -mean BMD of young reference population) / SD of BMD of reference population) ≤ − 2.50 at the lumbar spine, femoral neck, or total hip. Consistent with recommendations from the International Osteoporosis Foundation [22] and International Society for Clinical Densitometry [23] , T scores were calculated using National Health and Nutrition Examination Study III BMD norms for white women aged 20-29 years [24, 25] .
When the BMD T score was > − 2.50 in a given BMD measurement (pre-) and ≤ − 2.50 at the subsequent BMD measurement (post-), the date of Bincident^osteoporosis was estimated to be the midpoint of the pre-and post-visits.
Reference and classification variables
The primary reference variable (outcome) was hip fracture and the secondary reference variable was major osteoporotic fracture (clinical spine, forearm, hip, or shoulder fracture per FRAX® [14] definition) ascertained during full study followup.
The primary classification variable (predictor) was estimated to be a 10-year absolute risk of hip fracture calculated using FRAX® (http://www.shef.ac.uk/FRAX/) or the Garvan algorithm [9] with or without BMD, and without BMD using QFracture [10] . The secondary classification variable was estimated to be a 10-year absolute risk of major osteoporotic fracture calculated using the FRAX® or Garvan algorithm with or without BMD and without BMD using QFracture. The risk scores were calculated using externally generated parameter coefficients provided by the developers of these algorithms.
In the with-BMD analysis, tertiary classification variables were femoral neck BMD T score alone, and a variable for age plus femoral neck T score created using an internally generated logistic regression model. The latter classification variable corresponds to the estimated probability of fracture given age plus femoral neck T score as predictors with no interaction term. In the without-BMD analysis, continuous age and continuous BMI were tertiary classification variables.
Accounting for competing risks
To account for competing risks, only men who had a hip fracture or major osteoporotic fracture before developing a competing risk (antifracture treatment, death, or incident osteoporosis for the with-BMD analysis) were considered to be cases. The date of Bincident^treatment was estimated to be the midpoint of the pre-(no reported treatment) and post-visits (first reported treatment). Because competing risks cannot be components of an outcome, hip and clinical vertebral fractures were not competing risks in the analysis of incident major osteoporotic fracture. Because the presence of osteoporosis was only known if BMD was measured, osteoporosis was an exclusion criterion and a competing risk in the with-BMD analysis only.
Statistical analysis
Correlated ROC curve analysis for identification of incident fracture
We constructed receiver operating characteristic (ROC) curves to determine the area under the curve (AUC) and the corresponding 95% confidence intervals for each classification variable to identify the reference variable. Each point on the ROC curve marks the sensitivity and corresponding value of B1 − specificity^for a given cut point of the classification variable. The AUC is an overall estimate of the accuracy of the risk score to identify patients who had a hip or major osteoporotic fracture during follow-up. This area could range from 1 for a perfect test to 0.5 for a test that performs no better than chance.
For the correlated ROC curve analysis, we used the SAS %ROC macro-based on DeLong's methods for nonparametric comparison of areas under correlated ROC curves, i.e., ROC curves compared within the same population [26, 27] . The ROC curves were based on logistic regression to model the observed fracture incidence (reference variable) and estimation of 10-year probability of fracture using the calculated risk scores (classification variables). Separate correlated ROC curve analyses were conducted for the with-and without-BMD scores. Pairwise comparisons of the area under the curve for each classification variable vs. the QFracture (referent) were conducted using Chi-square tests with a Bonferroni correction for multiple comparisons, i.e., P < 0.01 was statistically significant for five pairwise comparisons.
Sensitivity and specificity to identify incident fracture
We calculated the sensitivity (true-positive fraction), 1 − specificity (false-positive fraction) and corresponding 95% confidence intervals for each classification variable to identify the reference variable. We adjusted risk tool threshold until 90% sensitivity was reached, then the associated specificity was calculated.
Assessment of model calibration
Model calibration (relationship between predicted probability and observed fracture incidence in the study population) of each risk score was assessed using the Hosmer-Lemeshow goodness-of-fit test [28, 29] . Using a Bonferroni correction for multiple comparisons, P < 0.01 was statistically significant with a small P value suggesting poor fit of the predicted fracture risk to the observed fracture incidence.
All analyses were performed using SAS 9.4 [30] or R version 3.3.3 [31] .
Results
Baseline characteristics of the 4944 participants in the analytic cohort for the primary analysis (with-BMD analysis for hip fracture) were tabulated ( Table 1 ). The mean age of the with-BMD cohort for hip fracture was 73.4 years (5.8), and the mean BMI was 27.6 kg/m 2 (3.8) (overweight).
Hip fracture
Correlated ROC curve analysis for hip fracture (Table 3 ; Online supplement eFig. 4). A correlated ROC curve analysis showed a statistically significant difference between the risk scores calculated without BMD compared with BMD (P < 0.0001 for comparison with QFracture as referent).
Sensitivity and specificity for hip fracture
The cut points necessary to achieve 90% sensitivity were less than 2% for all three risk tools (Tables 2 and 3 ). Continuous age alone predicted hip fracture risk and major osteoporotic fracture risk with 90% sensitivity using cut points of 69.5 years (Table 3 ) and 68.5 years (Table 5) , respectively.
Major osteoporotic fracture
Correlated ROC curve analysis for major osteoporotic fracture Correlated ROC curve and sensitivity and specificity analyses showed that the tools had similar but slightly lower accuracy to identify major osteoporotic fracture compared to findings for the hip fracture outcome (Tables 4 and 5 (Table 3) . Continuous BMI performed slightly better than chance to identify incident major osteoporotic fracture (AUC 0.57, 95% CI 0.53, 0.62).
Sensitivity and specificity for major osteoporotic fracture
The cut points necessary to achieve 90% sensitivity were less than 7% for all three risk tools (Tables 4 and 5 ). Continuous age predicted major osteoporotic fracture risk with 90% sensitivity using a cut point of 68.5 years.
Model calibration
The FRAX, Garvan tool, and QFracture were poorly calibrated; calibration plots revealed that the risk scores underestimated observed hip fracture incidence in the lowest deciles of scores and overestimated observed hip fracture incidence in the highest deciles of scores (Fig. 1) . The age plus femoral neck BMD T score and femoral neck BMD T score classification variables developed in the current study showed good calibration to the observed hip fracture incidence rates (Online supplement eTables 1 and 2).
Proportion identified by treatment-level FRAX scores and osteoporosis-level T score
In participants who had an incident hip fracture during follow-up, 72.6% had a treatment-level FRAX score (either 10-year risk of hip fracture ≥ 3% or 10-year risk of major osteoporotic fracture ≥ 20%) before the hip fracture; 99.6 % (271 out of the 272 hip fracture cases) reached age 70 before the hip fracture.
In participants who had an incident major osteoporotic fracture during follow-up, 8.5% had a treatment-level FRAX score (either 10-year risk of hip fracture ≥ 3% or 10-year risk of major osteoporotic fracture ≥ 20%) before the hip fracture; 98.1% (638 out of 650 cases) reached age 70 before the major osteoporotic fracture. Also, 82.2% of all men who developed osteoporosis were age 70 or older and 94.1% of all men who developed a treatment-level FRAX score (either 10-year risk of hip fracture All scores compared ----< 0.0001
These incident events were competing risks: clinical vertebral fracture, treatment (initiation of bisphosphonate, calcitonin, or teriparatide), osteoporosis by BMD criteria, and death a P value for Chi-square test with Bonferroni correction for multiple comparisons, where P < 0.01 is statistically significant b The logistic regression formula for the age plus femoral neck BMD T score classification variable was logit (incident hip fracture) = − 11.2554 + 0.0854 * age − 1.1544 * femoral neck BMD T score ≥ 3% or 10-year risk of major osteoporotic fracture ≥ 20%) were age 70 or older.
Effect of competing risks
Competing risks had minimal impact on the AUCs in the main analysis (to identify hip fracture) but were more influential in the analysis of major osteoporotic fracture. 
Discussion
We conducted a comparative diagnostic accuracy analysis of three fracture risk assessment tools for older men. Our findings suggest that a model based on age plus femoral neck BMD T score has discrimination similar to more complicated tools for identification of older men who will suffer a hip or major osteoporotic fracture. Among risk scores without BMD, all risk scores performed similarly to a model based on continuous age alone. Our findings were similar to past analyses except for weaker performance for QFracture in our study compared with other studies [12] . Continuous age identified hip fracture and major osteoporotic fracture with 90% sensitivity at a cut point of 70 years, which is recommended in some clinical practice guidelines as a reasonable age to begin BMD screening in older men [32, 33] . Ettinger and Ensrud et al. analyzed the diagnostic accuracy of FRAX® to identify hip fracture or major osteoporotic fracture in men aged 65 and older [34] . Accounting for mortality as a competing risk, they found that the FRAX® risk calculator without BMD was better calibrated to hip fracture than to major osteoporotic fracture. With the exception of the Garvan score calculated without BMD, we found poor calibration for risk scores using externally generated model parameters. As expected, our internally generated age plus femoral neck T score and femoral neck T score classification variables showed good calibration to the MrOS data. Our results appear to be consistent with a 2015 systematic review in which 7 of 15 studies reported poor calibration of at least one fracture risk All scores compared ----< 0.0001
These incident events were competing risks: treatment (initiation of bisphosphonate, calcitonin, or teriparatide), osteoporosis by BMD criteria, death a P value for Chi-square test with Bonferroni correction for multiple comparisons, where P < 0.01 is statistically significant b The logistic regression formula for the age plus femoral neck BMD T score classification variable was logit (incident major osteoporotic fracture) = −9.7882 + 0.0687 * age − 1.1457 * femoral neck BMD T score All scores compared ----< 0.0001
These incident events were competing risks: clinical vertebral fracture, treatment (bisphosphonate, calcitonin, or teriparatide), and death a P value for Chi-square test with Bonferroni correction for multiple comparisons, where P < 0.01 is statistically significant assessment instrument, with similar levels of calibration for simple (5 or fewer clinical variables) vs. more complicated risk tools [35] . Because direct comparison of tools with externally vs. internally generated parameters is prone to bias, the predictive ability of simple vs. more complex models needs to be confirmed in other cohorts. A 2014 systematic review and meta-analysis reported satisfactory diagnostic accuracy (AUC > 0.70) for 13 different fracture risk assessment tools that had been externally validated, with the best performance seen by QFracture (AUC 0.87, 95% CI 0.86 to 0.88 for men) [12] . Other analyses of QFracture also showed higher AUC values than were found in our analysis [10, 17, 36] . The poorer performance of QFracture in our analysis was probably largely due to the older age of our cohort compared to the QFracture development cohort (mean age 73.4 vs. 50 years, respectively). Kanis et al. reported that for hip fracture prediction, validated clinical risk factors for fracture and BMD had better discriminatory ability at younger ages, with the greatest discrepancy for older vs. younger cohorts seen for risk scores that incorporated both clinical risk factors and BMD [37, 38] . Our results may also differ because we excluded men with hip or spine fracture or treatment at baseline to account for competing risks; in contrast, patients with a previous recorded fracture were eligible for inclusion in the QFracture development cohort [36] . Also, risk factors including living in a nursing or care home and chronic liver disease assessed in the QFracture risk score were not present or not measurable in our cohort. Our results demonstrate that fracture risk assessment tools need to be compared within cohorts of the same individuals, as we have done in our correlated ROC curve analyses.
Our results have implications for primary care practice. The National Osteoporosis Foundation clinical practice guidelines recommend risk factor assessment and osteoporosis treatment for older men based on existing evidence supporting vertebral fracture reduction in men treated with bisphosphonates [32, 39, 40] . Our findings suggest that complicated tools should be reserved for patients for whom the clinician and/or patient himself wishes to obtain additional fracture risk estimates given unique risk factors such as rheumatoid arthritis or oral glucocorticoid use. The poor calibration of the externally generated risk scores suggests that recalibrated versions of FRAX, Garvan, and QFracture created specifically for adults aged 65 and older would be useful. In the absence of risk scores tailored to an older population, our results suggest that age plus femoral neck BMD T score is likely to perform as accurately as more complicated risk scores.
Our study had several limitations. The results are not generalizable to postmenopausal women or men under age 65, individuals with secondary causes of osteoporosis, or institutionalized individuals. Because most MrOS participants had good general health at baseline, the results may not be generalizable to men with multiple comorbid health conditions that could influence BMD and fracture. Ninety percent of the sample was white; results might differ for nonwhite individuals. Because of the designated endpoints of the risk tools, we only considered hip fracture and major osteoporotic fractures as outcomes; our results do not apply to clinical fractures at other sites or radiographic vertebral fractures. We included nontraumatic and traumatic fractures to decrease bias due to reporting error for fracture mechanism; the results cannot be generalized to traumatic fractures only. While the QFracture and Garvan tools include a component for falls history, these tools alone are not adequate for full assessment of the falls component of fracture risk in older men. The internal generation of our BMD-T score classifiers ensured good calibration in this study; the same results might not be seen in other cohorts. Some centers in the UK use a strategy in which patients with high-risk FRAX without BMD scores are treated and those with intermediate-risk scores are candidates for DXA testing [41] . Our competing risks assumptions are inconsistent with this strategy; therefore, our results do not reflect performance of FRAX when used in this manner. These incident events were competing risks: treatment (bisphosphonate, calcitonin, or teriparatide), death a P value for Chi-square test with Bonferroni correction for multiple comparisons, where P < 0.01 is statistically significant
Conclusions
Age plus femoral neck BMD T score predicted incident hip fracture or major osteoporotic fracture as accurately as the Garvan, FRAX and QFracture risk scores calculated with or without BMD in men aged 65 and older. The externally developed risk scores were poorly calibrated to hip fracture incidence in an older male study population. Age 70 or older identified hip fracture and major osteoporotic fracture with 90% sensitivity. Predicted fracture risk
Observed fracture risk
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